GHRP-6 side effects by evidence tier: the hunger that follows from its ghrelin receptor, what single-dose human studies recorded, the animal cytoprotection data, and what no trial has measured.
The defining side effect of GHRP-6 is not a side effect in the usual sense. It is hunger, and it follows directly from the receptor the peptide activates — the same one ghrelin, the stomach's appetite hormone, uses to signal the hypothalamus. Everything else the human literature records comes from single doses given to volunteers in physiology studies; everything about repeated use is inference. This page separates what was measured from what is assumed. It is a research reference beside the GHRP-6 profile, not a safety assessment or medical advice.
GHRP-6 was built in 1984, before anyone knew what it bound to. The receptor — the growth hormone secretagogue receptor, GHS-R1a — was cloned in 1996 (Howard and colleagues, Science) using GHRP-family ligands, and its natural ligand, ghrelin, was identified in 1999 (Kojima and colleagues, Nature). GHRP-6 is therefore a ghrelin mimetic that predates ghrelin, and the ghrelin receptor explains its profile completely: in the pituitary it releases GH; in the arcuate nucleus of the hypothalamus it drives the NPY and AgRP neurons that signal hunger. Human studies reported increased hunger and food intake after GHRP-6 years before ghrelin infusion studies reproduced the effect almost exactly, a history Kojima and Kangawa set out in their review (Physiological Reviews, 2005).
Within the family, GHRP-6 carries the strongest appetite signal — stronger than GHRP-2, far stronger than ipamorelin, which was engineered specifically to avoid it. Two things follow. Hunger after a dose is expected and reproducible, not an idiosyncratic reaction. And the consequence under repeated dosing — weight gain from a sustained orexigenic signal — is the most obvious chronic effect the compound could have, and no study has measured it.
GHRP-6 was given to many hundreds of volunteers from the late 1980s through the 2000s: healthy adults, children, older adults and patients with pituitary disease, most often as a single 1 µg/kg intravenous bolus (Bowers and colleagues, Journal of Clinical Endocrinology and Metabolism, 1990). The consistent findings, reviewed by Ghigo and colleagues (European Journal of Endocrinology, 1997), were increased hunger, transient flushing or warmth, and modest rises in cortisol, ACTH and prolactin. Some studies reported transient drowsiness. No study reported a serious adverse event attributable to the peptide.
The hormonal signals deserve calibration. GHRP-6 raises cortisol and prolactin less than GHRP-2 or hexarelin and more than ipamorelin; the rises after a single dose were modest and short-lived. But the same receptor distribution that produces them — GHS-R1a in the hypothalamic–pituitary–adrenal axis and on lactotroph cells — is engaged every time the peptide is given, and the effect of engaging it two or three times daily for months has not been studied.
The animal safety record is indirect. Berlanga and colleagues at a Cuban research institute published rodent and porcine studies in which GHRP-6 reduced infarct size and protected against ischaemia–reperfusion injury and organ fibrosis, using substantially higher weight-based doses than the human probe studies, delivered intraperitoneally or intravenously around an injury. These are efficacy models, not toxicology, and they come largely from one group. That the animals tolerated those doses in an injury setting says little about repeated use in healthy humans, and the cytoprotective findings themselves have not been tested in people.
No trial administered GHRP-6 repeatedly for months and followed participants, so the consequences of sustained ghrelin-receptor stimulation are inferred rather than observed. The open questions are specific to this compound as much as to the class:
Outside the literature, community reports describe persistent hunger, water retention, tingling and lethargy. These are unblinded self-reports with no denominator; they cannot establish incidence or causation. The research overview covers the mechanism behind each signal and the secretagogues primer places the class-wide concerns in context.
Some share of reactions in unregulated use plausibly traces to the vial rather than the molecule: synthesis impurities, endotoxin or degraded material. GHRP-6 has two tryptophan residues, which make it moderately light-sensitive in solution, so a reconstituted vial left in the light is a different preparation from a fresh one; the cold-chain and shelf-life guide covers the storage rules. It also shares four of six residues with GHRP-2 and is sold by the same suppliers, so HPLC purity alone does not confirm which compound a vial contains — mass-spectrometry identity does. Every lot of GHRP-6 5MG is third-party tested, as described under lab testing and COAs, and the certificate of analysis entry explains what to look for.
GHRP-6 has no Health Canada market authorisation and no DIN; it is not a controlled substance in Canada and is sold here for research use only. It was never developed to registration by any company and has no approval anywhere. In September 2023 the U.S. FDA placed GHRP-6 in category 2 of its section 503A compounding evaluation, citing the absence of adequate safety data — the gap this page describes. The World Anti-Doping Agency lists growth hormone-releasing peptides under S2 and names GHRP-6, so it is prohibited for tested athletes at all times.
Why does GHRP-6 cause hunger? Because it activates GHS-R1a, the receptor ghrelin uses to signal hunger through NPY and AgRP neurons in the hypothalamus. The effect was documented in human studies before ghrelin was discovered and is the main reason GHRP-6 is distinguished from ipamorelin.
What did single-dose human studies report? Increased hunger, transient flushing or warmth, occasional drowsiness, and modest rises in cortisol, ACTH and prolactin after a 1 µg/kg intravenous bolus. No serious adverse events were attributed to the peptide.
Does GHRP-6 raise cortisol as much as GHRP-2? No. The comparative literature places GHRP-6 below GHRP-2 and hexarelin on cortisol and prolactin release, and above ipamorelin. Its distinctive signal is appetite, not cortisol.
Is there any long-term safety data? No. There are no repeated-dose human studies over months, and the animal data comes from injury models rather than toxicology. Weight gain, glucose handling and prolactin under chronic dosing are all unmeasured.
Is this medical advice? No. GHRP-6 is a research-grade compound for laboratory use only, not for human or veterinary use. This page summarises what published studies recorded; it is not a safety assurance, a risk assessment or a recommendation.
